BBHC
ENTA icon

Brown Brothers Harriman & Co’s Enanta Pharmaceuticals ENTA Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-93
Closed -$3K – 825
2016
Q4 		$3K Hold
93
– – ﹤0.01% 812
2016
Q3 		$2K Hold
93
– – ﹤0.01% 747
2016
Q2 		$2K Buy
+93
New +$2.43K ﹤0.01% 786

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
MCM
Matarin Capital Management New York $409M AUM 33.03% 1-Year Est. Return

Brown Brothers Harriman & Co's ENTA Position: Q1 2017 in Review

Brown Brothers Harriman & Co sold out of Enanta Pharmaceuticals (ENTA) in Q1 2017, closing a stake of 93 shares — an estimated $3K sold.

Brown Brothers Harriman & Co first reported a position in ENTA in Q2 2016 and held it in 3 quarters. The position peaked at $3K in Q4 2016. 126 funds tracked by Wall St. Rank hold ENTA as of Q1 2017.

  • Brown Brothers Harriman & Co reported no remaining Enanta Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 93 Enanta Pharmaceuticals shares in Q1 2017, an estimated $3K.
  • Brown Brothers Harriman & Co first reported a position in Enanta Pharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Brown Brothers Harriman & Co's Enanta Pharmaceuticals position peaked at $3K in Q4 2016.
  • 126 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2017.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2017, filed 12 May 2017.